Acurx Pharmaceuticals Presents Abstract and Poster Presentation at IDWeek: New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for C. difficile Infections
Acurx Pharmaceuticals Presents Abstract and Poster Presentation at IDWeek: New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for C. difficile Infections
Acurx Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021: Title: An Open-label Phase 2a study…
View On WordPress
